The DOI matches its Crossref record.
Escherichia coli‐based cell‐free synthesis of virus‐like particles
Abstract
Virus‐like particles (VLP) have received considerable attention for vaccine, drug delivery, gene therapy and material science applications. Although the number of unique VLP and their applications are rapidly growing, the positive impact of VLP applications is limited by the current diverse, expensive, and typically low‐yielding production technologies available. These technologies, when scaled, often result in structurally and compositionally inconsistent products. We present Escherichia coli‐based cell‐free protein synthesis as a production technology to overcome many of the limitations of current VLP production processes. Using this technique, the MS2 bacteriophage coat protein VLP was produced at a yield 14 times the best published production yield. Also, a C‐terminally truncated Hepatitis B core protein VLP was produced at similarly high yields (6 × 10 13 VLP/mL). These VLP were found to have comparable characteristics to those produced in vivo. The scalability of this technology was tested without loss in production yields. To our knowledge, this is the first time a prokaryote‐based in vitro transcription/translation system has generated a virus‐like particle. Biotechnol. Bioeng. 2008;100: 28–37. Biotechnol. Bioeng. 2008;100: 28–37. © 2007 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 869
Virus-like particles in vaccine development
Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.115 · Cited by 845
Cell-free protein synthesis: Applications come of age
Carlson, E. D., Gan, R., Hodgman, C. E., & Jewett, M. C. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.09.016 · Cited by 706
Cell-free gene expression: an expanded repertoire of applications
Silverman, A. D., Karim, A. S., & Jewett, M. C. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0186-3 · Cited by 593
Cell-free synthetic biology: Thinking outside the cell
Hodgman, C. E., & Jewett, M. C. (2012) · Metabolic Engineering · doi:10.1016/j.ymben.2011.09.002 · Cited by 425
The All E. coli TX-TL Toolbox 2.0: A Platform for Cell-Free Synthetic Biology
Garamella, J., Marshall, R., Rustad, M., & Noireaux, V. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00296 · Cited by 419
Bioengineering virus‐like particles as vaccines
Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P., Wibowo, N., & Middelberg, A. P. J. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25159 · Cited by 355
Cell-Specific Delivery of Diverse Cargos by Bacteriophage MS2 Virus-like Particles
Ashley, C. E., Carnes, E. C., Phillips, G. K., Durfee, P. N., Buley, M. D., Lino, C. A., Padilla, D. P., Phillips, B., Carter, M. B., Willman, C. L., et al. (2011) · ACS Nano · doi:10.1021/nn201397z · Cited by 350
Protein Nanoparticles: Promising Platforms for Drug Delivery Applications
Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01098 · Cited by 308
Enhancing phage therapy through synthetic biology and genome engineering
Lenneman, B. R., Fernbach, J., Loessner, M. J., Lu, T. K., & Kilcher, S. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.11.003 · Cited by 208
Ayoubi‐Joshaghani, M. H., Dianat‐Moghadam, H., Seidi, K., Jahanban‐Esfahalan, A., Zare, P., & Jahanban‐Esfahlan, R. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27248 · Cited by 52
Metadata
- Authors
- Bundy, B. C., Franciszkowicz, M. J., & Swartz, J. R.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2007-11-19
- Volume
- 100
- Issue
- 1
- Pages
- 28-37
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2089190345
- Cited by
- 179
- References
- 0
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
